PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2  +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidel...

Source: World Journal of Surgical Oncology - September 18, 2023 Category: Cancer & Oncology Authors: Xiaoyu Liu, Zhaoyun Liu, Chao Li, Xiang Song, Xinzhao Wang, Sumei Li and Zhiyong Yu Tags: Research Source Type: research